Monday, July 01, 2024
Dawn Health, a digital health company focused on patient-centric innovation, has announced a collaboration with Merck, a leading global pharmaceutical company, to develop a digital solution for growth hormone disorders (GHD).
Over the next two years, they aim to create an advanced, user-friendly digital platform to enhance the lives of tens of thousands of patients across more than 40 countries.
Utilizing the latest AI technologies, the partnership will explore integrating features such as growth predictions and advanced personalization into the platform.
The goal is to improve user experience, adoption, adherence, and treatment outcomes.
This digital solution will support children and young adults with GHD, offering tools and assistance to their caregivers both at home and in clinical settings.
With a shared commitment to improving patient lives, the collaboration will focus on delivering an intuitive and engaging product.
This involves understanding the unmet needs of patients and addressing them, as well as listening to caregivers and healthcare professionals to empower and support those living with GHD.
The project is already off to a strong start, with initial workshops and discussions between the Dawn Health and Merck teams.
Together, they are working to create a cutting-edge platform that will globally improve the lives of people living with growth hormone disorders.
Source: prnewswire.com
